Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous dendritic cells loaded with MAGE-A3, MelanA and survivin
- Development stage
- Phase 2
- Lead developer
- University Hospital Erlangen
- Modality
- Vaccines & Immunotherapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intradermal, Subcutaneous, Intravenous
01
Overview
This is a personalized cancer immunotherapy in which a patient's own (autologous) dendritic cells are harvested, then ex vivo loaded with tumor-associated antigens—specifically mRNA encoding melanoma-associated antigen A3 (MAGE-A3), MelanA (also known as MART-1), and survivin. The resulting vaccine is designed to stimulate the patient’s immune system to recognize and attack cancer cells expressing these antigens. Dendritic cell vaccines work by presenting tumor antigens to T-cells, thereby inducing a targeted cytotoxic immune response against the tumor. This approach has been investigated primarily for metastatic melanoma but may have broader applications in other cancers expressing these antigens[2][3][4].
- Other names
- autologous dendritic cell vaccine loaded with MAGE-A3, MelanA and survivin
02
Targets
MART-1 TCR (MART-1-specific T-cell receptor)MAGE-A3 TCR (T cell receptor / peptide–MHC complex derived from MAGE-A3/A6)
Beyond the preview
Go deeper on autologous dendritic cells loaded with MAGE-A3, MelanA and survivin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous dendritic cells loaded with MAGE-A3, MelanA and survivin.